KRW 5690.0
(1.43%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 18.6 Billion KRW | -4.68% |
2022 | 17.68 Billion KRW | 39.33% |
2021 | 12.69 Billion KRW | 47.57% |
2020 | 8.6 Billion KRW | 26.84% |
2019 | 6.78 Billion KRW | -3.89% |
2018 | 7.05 Billion KRW | 61.78% |
2017 | 4.36 Billion KRW | 144.66% |
2016 | 1.78 Billion KRW | 22.27% |
2015 | 1.45 Billion KRW | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 3.8 Billion KRW | -3.12% |
2024 Q1 | 3.94 Billion KRW | -6.93% |
2023 Q3 | 4.77 Billion KRW | 29.72% |
2023 Q1 | 4.15 Billion KRW | 3.74% |
2023 FY | 16.86 Billion KRW | -4.68% |
2023 Q4 | 4.24 Billion KRW | -11.21% |
2023 Q2 | 3.68 Billion KRW | -11.38% |
2022 Q1 | 3.79 Billion KRW | -23.12% |
2022 FY | 17.68 Billion KRW | 39.33% |
2022 Q4 | 4 Billion KRW | -30.5% |
2022 Q3 | 5.76 Billion KRW | 39.91% |
2022 Q2 | 4.12 Billion KRW | 8.52% |
2021 Q1 | 1.84 Billion KRW | -42.84% |
2021 Q2 | 2.14 Billion KRW | 16.18% |
2021 Q3 | 3.77 Billion KRW | 76.26% |
2021 FY | 12.69 Billion KRW | 47.57% |
2021 Q4 | 4.93 Billion KRW | 30.87% |
2020 Q4 | 3.22 Billion KRW | -89.4% |
2020 Q2 | 36.66 Billion KRW | 1799.14% |
2020 Q1 | 1.93 Billion KRW | -58.5% |
2020 FY | 8.6 Billion KRW | 26.84% |
2020 Q3 | 30.41 Billion KRW | -17.05% |
2019 Q3 | 1.69 Billion KRW | -7.53% |
2019 FY | 6.78 Billion KRW | -3.89% |
2019 Q4 | 4.65 Billion KRW | 174.89% |
2019 Q2 | 1.82 Billion KRW | 39.17% |
2019 Q1 | 1.31 Billion KRW | 46.29% |
2018 Q3 | 37.1 Billion KRW | 0.0% |
2018 Q4 | 898.83 Million KRW | -97.58% |
2018 FY | 7.05 Billion KRW | 61.78% |
2017 FY | 4.36 Billion KRW | 144.66% |
2016 FY | 1.78 Billion KRW | 22.27% |
2015 FY | 1.45 Billion KRW | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 78.35 Billion KRW | 76.258% |
InBody Co.,Ltd | 87.36 Billion KRW | 78.706% |
Curexo Inc. | 18.16 Billion KRW | -2.425% |
Seegene, Inc. | 210.08 Billion KRW | 91.145% |
i-SENS, Inc. | 91.12 Billion KRW | 79.586% |
Ray Co., Ltd. | 59.03 Billion KRW | 68.486% |
Gencurix Inc. | 12.79 Billion KRW | -45.361% |
L&C Bio Co., Ltd | 25.86 Billion KRW | 28.063% |